IGF1 and breast carcinoma: Progestin stimulation prior to IGF-1 treatment of PR+ breast carcinoma cells upregulates IRS-2 expression levels and tyrosine phosphorylation, thereby enhancing downstream IRS-2-dependent signals [105-107].